Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6569637 | 0.98 | L3MBTL1 (0.60) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL7833006 | 0.93 | L3MBTL1 (0.55) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL7833009 | 0.89 | L3MBTL1 (0.51) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL394073 | 0.83 | L3MBTL1 (0.60) | L3MBTL1KDM4ETSHRTLR7MAP2K1 | |
| SCHEMBL27832422 | 0.82 | EGLN2 (0.49) | L3MBTL1KDM4EEGLN2FTOLMNA | |
| SCHEMBL69177 | 0.82 | L3MBTL1 (0.64) | L3MBTL1KDM4ETSHRMAP2K1ALOX15 | |
| SCHEMBL3653582 | 0.81 | L3MBTL1 (0.58) | L3MBTL1KDM4EMAP2K1ALOX15HTT | |
| SCHEMBL28048185 | 0.81 | TLR7 (0.48) | L3MBTL1KDM4EEGLN2FTOLMNA | |
| SCHEMBL27847395 | 0.81 | EGLN2 (0.47) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL3422060 | 0.81 | EGLN2 (0.47) | L3MBTL1KDM4EEGLN2FTOLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457345-A | Hydroxy pyridine aldoxime skeleton | 国家科学研究中心 | 2023-07-18 | — | — | CN | claimed |
| CN-105348282-A | HIV-1 integrase inhibitor compound as well as preparation method and application thereof | UNIV BEIJING TECHNOLOGY | 2016-02-24 | — | — | CN | claimed |
| CN-105294781-A | Iridium-europium heterogeneous polynuclear metal complex and its preparation method and use | UNIV XIANGTAN | 2016-02-03 | — | — | CN | claimed |
| US-20260103451-A1 | PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | BEYONDBIO INC (KR) | 2026-04-16 | — | — | US | disclosed |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12371418-B2 | Process for preparing pyrimidinyl bipyridine compound and intermediate therefor | BEYONDBIO INC. (KR) | 2025-07-29 | — | — | US | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-0249707-A1 | Picolinic acid derivatives and herbicidal compositions | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1987-12-23 | — | — | EP | disclosed |
| EP-0045281-B1 | TRIAZOLINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CIBA-GEIGY AG (CH) | 1985-05-08 | — | — | EP | disclosed |
| US-4426526-A | HISTAMINE ANTAGONISTS, ANTIINFLAMMATORY, ANTISECRETORY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-01-17 | — | — | US | disclosed |
| US-4406905-A | COMPLEXING, ANTIBIOTICS | CIBA-GEIGY CORPORATION (US) | 1983-09-27 | — | — | US | disclosed |
| EP-0045281-A1 | Triazoline derivatives and processes for their preparation | CIBA-GEIGY AG (CH) | 1982-02-03 | — | — | EP | disclosed |
| US-4264608-A | HISTAMINE ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-04-28 | — | — | US | disclosed |
| US-4215126-A | HISTAMINE H2 BLOCKING | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1980-07-29 | — | — | US | disclosed |
| US-4156727-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-29 | — | — | US | disclosed |
| US-4154838-A | ANTIHISTAMINE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | L3MBTL1 4709/4885CA12 4411/4885CA1 4627/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | L3MBTL1 4709/4885CA12 4411/4885CA1 4627/4885 |
| US-20260103451-A1 | PROCESS FOR PREPARING PYRIMIDINYL BIPYRIDINE COMPOUND AND INTERMEDIATE THEREFOR | CCND1, CCND2, CDK2 | L3MBTL1 2295/4885CA12 4541/4885CA1 1741/4885 |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, RAD1, CHEK2 | L3MBTL1 828/4885CA12 2793/4885CA1 2028/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | L3MBTL1 2943/4885CA12 2545/4885CA1 3143/4885 |
| US-12371418-B2 | Process for preparing pyrimidinyl bipyridine compound and intermediate therefor | WEE1, GGPS1, WEE2 | L3MBTL1 4602/4885CA12 4818/4885CA1 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.